Clinical Trials Logo

Calciphylaxis clinical trials

View clinical trials related to Calciphylaxis.

Filter by:

NCT ID: NCT06283589 Recruiting - Calciphylaxis Clinical Trials

The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis

Start date: February 12, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if multiple doses of INZ-701, given once per week over 4 weeks are safe and increase pyrophosphate (PPi) levels in hemodialysis-dependent (HD) end stage kidney disease (ESKD) study participants who have low PPi levels. In addition, the effect of hemodialysis on the pharmacokinetics of INZ-701 and PPi levels will be evaluated.

NCT ID: NCT06065852 Recruiting - Fabry Disease Clinical Trials

National Registry of Rare Kidney Diseases

RaDaR
Start date: November 6, 2009
Phase:
Study type: Observational [Patient Registry]

The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research is to: - Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition. - Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better. - Further the development of future treatments. Participants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.

NCT ID: NCT05633121 Completed - Rheopheresis Clinical Trials

Retrospective Study Evaluating the Contribution of Rheopheresis in the Treatment of Uremic Calciphylaxis (RHEO-CUA)

RHEO-CUA
Start date: May 20, 2021
Phase:
Study type: Observational

Calcifying uremic arteriolopathy (or uremic calciphylaxis) is a rare disease (prevalence <1% of dialysis patients), but the prognosis is often catastrophic. The main non-modifiable risk factors are age, female gender, diabetes, obesity and length of time on dialysis. Today, there is no specific treatment for this pathology, and the therapeutic management is poorly codified. However, it is commonly accepted that the treatment is based on the control of risk factors, local care, and the possible addition of treatment with sodium thiosulfate. Hyperbaric oxygen therapy has also been proposed by some authors, but remains not very accessible in practice. Recently, it has been proposed to use Rheopheresis as an adjuvant treatment for severe forms of uraemic calciphylaxis. It is a technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications. The aim of this study is to propose a large national retrospective study, studying the evolution of patients with uremic calciphylaxis and treated by rheopheresis, compared to a control group. This will allow to have a more precise idea of the contribution of Rheopheresis in this indication.

NCT ID: NCT05018221 Recruiting - Calciphylaxis Clinical Trials

Better Evidence and Translation for Calciphylaxis

BEAT-Calci
Start date: August 26, 2021
Phase: Phase 3
Study type: Interventional

This global platform study will evaluate multiple interventions, across several domains of therapeutic care, in adult patients with kidney failure and newly diagnosed calciphylaxis.

NCT ID: NCT04654000 Enrolling by invitation - Clinical trials for End Stage Renal Disease

Rheopheresis as Adjuvant Treatment of Calciphylaxis

RHEO-CAL
Start date: May 2023
Phase: N/A
Study type: Interventional

We propose to set up a prospective randomized controlled trial to control the security and assess the efficacy of adjuvant treatment by rheopheresis in necrotizing-ulcered calciphylaxis in the hemodialysis population.

NCT ID: NCT04592640 Active, not recruiting - Clinical trials for Chronic Kidney Diseases

Stem Cells for Uremic Calciphylaxis Patients

Start date: September 17, 2018
Phase: N/A
Study type: Interventional

Treatment for Uremic Calciphylaxis Patients with Human Amniotic Mesenchymal Stem Cells

NCT ID: NCT04195906 Completed - Calciphylaxis Clinical Trials

Phase 3 Study of SNF472 for Calciphylaxis

Calciphyx
Start date: February 12, 2020
Phase: Phase 3
Study type: Interventional

The primary objectives are to assess the efficacy, safety, and tolerability of SNF472 compared to placebo when added to background care for the treatment of calciphylaxis (CUA).

NCT ID: NCT03319914 Terminated - Calciphylaxis Clinical Trials

Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate

OF-CALISTA
Start date: October 20, 2017
Phase:
Study type: Observational

This is an 8-week observational follow-up study of patients who participated in the ST-001 CALISTA study (A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial).

NCT ID: NCT03150420 Terminated - Calciphylaxis Clinical Trials

A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients

CALISTA
Start date: May 24, 2017
Phase: Phase 3
Study type: Interventional

This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of intravenous Sodium Thiosulfate Injection for treatment of acute calciphylaxis-associated pain in chronic hemodialysis patients.

NCT ID: NCT03146793 Recruiting - Clinical trials for Renal Insufficiency, Chronic

The Early Administration of Sodium Thiosulfate Should Help to Reduce the Mortality of Dialysis Patients With Calciphylaxis, From a National Cohort

Start date: May 1, 2017
Phase: N/A
Study type: Observational

The national drug safety agency authorizes nominatively the use of sodium thiosulfate in dialysis patients with calciphylaxis. To date, it is the largest global cohort (more 600 patients from 2012 to 2016). We wanted to study retrospectively the fate of these patients at 6 months including mortality. Early use improves effectiveness.